Charles Schwab’s Carisma Therapeutics CARM Stock Holding History

Charles Schwab’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-60,952	Closed	-$138K	–	3633
2024 Q1	$138K	Sell	60,952 -11,791	-16%	-$28.3K	﹤0.01%	3278
2023 Q4	$213K	Hold	72,743	–	–	﹤0.01%	3271
2023 Q3	$308K	Hold	72,743	–	–	﹤0.01%	3207
2023 Q2	$638K	Buy	+72,743	New	+$396K	﹤0.01%	2938
2023 Q1	–	Sell	-3,395	Closed	-$41.4K	–	3557
2022 Q4	$41.4K	Hold	3,395	–	–	﹤0.01%	3398
2022 Q3	$29K	Hold	3,395	–	–	﹤0.01%	3439
2022 Q2	$56K	Sell	3,395 -22,389	-87%	-$256K	﹤0.01%	3379
2022 Q1	$311K	Hold	25,784	–	–	﹤0.01%	3209
2021 Q4	$421K	Buy	25,784 +1,507	+6%	+$30.3K	﹤0.01%	3200
2021 Q3	$386K	Buy	24,277 +2,758	+13%	+$132K	﹤0.01%	3213
2021 Q2	$1.99M	Buy	21,519 +18,701	+664%	+$1.19M	﹤0.01%	2715
2021 Q1	$147K	Hold	2,818	–	–	﹤0.01%	3352
2020 Q4	$77K	Buy	2,818 +2,268	+412%	+$57.5K	﹤0.01%	3333
2020 Q3	$16K	Hold	550	–	–	﹤0.01%	3323
2020 Q2	$8K	Hold	550	–	–	﹤0.01%	3316
2020 Q1	$7K	Hold	550	–	–	﹤0.01%	3222
2019 Q4	$12K	Hold	550	–	–	﹤0.01%	3169
2019 Q3	$13K	Hold	550	–	–	﹤0.01%	3168
2019 Q2	$17K	Sell	550 -1,868	-77%	-$55.9K	﹤0.01%	3206
2019 Q1	$50K	Buy	+2,418	New	+$41.8K	﹤0.01%	3126

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab's CARM Position: Q2 2024 in Review

Charles Schwab sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 60,952 shares — an estimated $138K sold.

Charles Schwab first reported a position in CARM in Q1 2019 and held it in 20 quarters. The position peaked at $1.99M in Q2 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

Charles Schwab reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
Charles Schwab sold 60,952 Carisma Therapeutics shares in Q2 2024, an estimated $138K.
Charles Schwab first reported a position in Carisma Therapeutics in Q1 2019 and held it in 20 quarters.
Charles Schwab's Carisma Therapeutics position peaked at $1.99M in Q2 2021.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.